日前，南华生物医药股份有限公司（000504.SZ，*ST生物）发布公告，正式终止筹划近半年的重 大资产重组事项。 公司原计划收购湖南慧泽生物医药科技有限公司（简称"慧泽生物医药"）51%的股权，以期拓展生 物医药板块，但最终因交易各方未能就交易方案达成一致而宣告终止。 业绩困境 *ST生物的前身是1992年上市的港澳实业，经历多次易主与更名，于2015年定名"南华生物"进军生 物医疗领域。 公司长期主营"生物医药"（干细胞、免疫细胞储存）和"节能环保"双主业。但其业绩始终起伏不 定，核心的干细胞治疗研究产业化缓慢，收入仍依赖细胞储存业务。 回溯过去，公司已多次在"ST"和"摘帽"间徘徊：因2014年至2015年连续亏损，2016年被ST；2017 年摘帽；又因连续两年亏损，2019年再次被*ST；2021年再度摘帽。 2025年4月，因触及"净利润为负且营收低于1亿元"的财务指标，公司第三次被实施退市风险警示。 2025年上半年，公司营收仍同比下滑8.40%，在此背景下，收购金弘新材成为其打破僵局、寻求生 路的重要战略落子。 2025年8月12日，*ST生物披露了《关于筹划重大资产重组暨签署股权收购意向协议 ...

星标 ★ IPO日报 精彩文章第一时间推送 日前，南华生物医药股份有限公司（000504.SZ，*ST生物）发布公告，正式终止筹划近半年的重大资产重组事项。 公司原计划收购湖南慧泽生物医药科技有限公司（简称"慧泽生物医药"）51%的股权，以期拓展生物医药板块，但最终因交易各方未能就交易方案达成一 致而宣告终止。 2025年上半年，公司营收仍同比下滑8.40%，在此背景下，收购金弘新材成为其打破僵局、寻求生路的重要战略落子。 2025年8月12日，*ST生物披露了《关于筹划重大资产重组暨签署股权收购意向协议的提示性公告》，宣布拟收购程泽能、易木林、长沙君合致远企业管 理咨询合伙企业（有限合伙）、长沙市履方医药信息咨询合伙企业（有限合伙）合计持有的慧泽生物医药51%股权。 张力制图 业绩困境 *ST生物的前身是1992年上市的港澳实业，经历多次易主与更名，于2015年定名"南华生物"进军生物医疗领域。 公司长期主营"生物医药"（干细胞、免疫细胞储存）和"节能环保"双主业。但其业绩始终起伏不定，核心的干细胞治疗研究产业化缓慢，收入仍依赖细胞 储存业务。 回溯过去，公司已多次在"ST"和"摘帽"间徘徊：因2014年至 ...

*ST生物（000504）重大资产重组告终。 回溯原委，去年8月*ST生物公告，公司筹划以现金方式收购慧泽医药51%股权，交易完成后，慧泽医药将成 为公司控股子公司。初步测算，此次交易预计构成重大资产重组情形。 慧泽医药是一家专注于药物研发及临床评价的专业CRO公司，85%以上的收入来源于临床评价服务。截至目 前，慧泽医药与国内外三百多家医药（含器械）企业及药学CRO、科研院所等建立了长期、友好的战略合 作伙伴关系，已完成各类型技术服务项目总计超过1000项。 据悉，*ST生物主要从事"生物医药"和"节能环保"两个板块的业务以及其他生物医药相关产品的生产销售或 代理销售等。其中，"生物医药"板块业务主要包括干细胞、免疫细胞储存及技术服务、干细胞应用研究、医 疗器械采购和销售等。 *ST生物表示，收购慧泽医药，一方面有利于上市公司生物医药板块业务发展延伸，从而进一步增强上市公 司主营业务的盈利能力，提升上市公司抗风险能力；另一方面细胞临床转化研究和药物研发及临床评价业务 上具有较强的关联性，通过资产整合，将有利于提升公司经营效率，具有较强的协同效应。 *ST生物1月22日公告，公司于2025年8月12日披露了《 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ *ST生物（维权）（000504）重大资产重组告终。 *ST生物1月22日公告，公司于2025年8月12日披露了《关于筹划重大资产重组暨签署股权收购意向协议 的提示性公告》，本次筹划重组事项尚未进入正式实施阶段，交易各方未达成实质性协议。 时隔5个月后，重组失败。2026年1月22日公司与交易各方签署了《股权收购意向协议之终止协议》，终 止筹划收购湖南慧泽生物医药科技有限公司（简称"慧泽医药"）51%股权的重大资产重组事项。 *ST生物表示，收购慧泽医药，一方面有利于上市公司生物医药板块业务发展延伸，从而进一步增强上 市公司主营业务的盈利能力，提升上市公司抗风险能力；另一方面细胞临床转化研究和药物研发及临床 评价业务上具有较强的关联性，通过资产整合，将有利于提升公司经营效率，具有较强的协同效应。 事实上，筹划重组前，*ST生物于2025年4月30日起被实施退市风险警示，公司股票简称由"南华生 物"变更为"*ST生物"。 就重组失败原因，*ST生物表示，交易各方对本次重大资产重组交易方案进行了多次协商和谈判，未能 最终达成一致。为切实维护 ...

在妇产科领域， 宫腔粘连 （IUA） 作为子宫内膜损伤后的常见并发症，传统治疗手段难以实现子宫内膜的结构与功能同步修复，而 水凝胶 作为兼具生物相容性与靶向递送能力 的新型载体，为IUA治疗提供了突破性方向。 课程信息 课程主题： 水凝胶在宫腔粘连治疗的研究 赛业云课堂有幸邀请到上述研究的 第一作者 ——上海市第一妇婴保健院 张东海 博士 ， 于12月23日（周二）晚7点做客直播间，为大家带来「 水凝胶在宫腔粘连治疗 的研究 」线上讲座。届时将 深度拆解两篇高分论文的研究设计、关键数据与创新逻辑，学习如何从临床痛点出发，设计兼具科学性与实用性的水凝胶治疗方案、细胞/ 药物负载策略到机制验证的完整科研逻辑，为水凝胶、干细胞相关领域研究提供可借鉴的创新路径 。 欢迎感兴趣的老师扫码报名，与顶刊一作在线交流互动，成功提交报名还可抽取「 赛业生物2026主题台历 和 疯狂动物城主题马克杯 」等好礼！ 课程时间： 2025年12月23日（周二）19:00-20:00 分享要点： 讲师介绍 张东海 博士 上海市第一妇婴保健院 同济大学附属妇产科医院 （上海市第一妇婴保健院） 周倩 教授 聚焦 IUA 这一临床难题，在 A ...

Core Viewpoint - The company, Kaineng Health, is increasing its investment in the cell industry by acquiring assets from its affiliated companies for 204 million yuan, aiming to establish a second growth curve in the health sector [2][6]. Group 1: Acquisition Details - Kaineng Health's wholly-owned subsidiary, Hainan Kaineng Cell, plans to acquire 100% equity of four companies under the Yuaneng Group, including Yuan Tian Biological and Lishui Dongxin, for a total of 204 million yuan [3][5]. - The acquisition involves companies that are all under the same control of Yuaneng Group, ensuring that the control relationship remains unchanged post-acquisition [3]. - The acquisition is classified as a related party transaction due to Kaineng Health's significant shareholding (43.70%) in Yuaneng Group and shared leadership [3][4]. Group 2: Financial Performance - For the first three quarters of 2025, Kaineng Health reported a revenue of 1.356 billion yuan, an increase of 8.1% year-on-year, and a net profit attributable to shareholders of 95.35 million yuan, up 13.29% [2][6]. - The target companies have reported losses, with revenues of 36.63 million yuan and 28.16 million yuan for 2024 and the first nine months of 2025, respectively, and net losses of 21.20 million yuan and 21.86 million yuan [7][8]. Group 3: Strategic Intent - The acquisition is part of Kaineng Health's strategy to strengthen its position in the health industry, leveraging its existing water purification business to enhance its cell industry investments [6][8]. - The company aims to support the acquired entities with resources and funding to foster growth and innovation in health-related products and technologies [6][8].

Core Viewpoint - Kaineng Health plans to acquire 100% equity of four target companies for approximately 204 million yuan, aiming to deepen its presence in the health industry and establish a second growth curve in the cell industry [1][2]. Group 1: Acquisition Details - The acquisition involves Kaineng Health's wholly-owned subsidiary, Kaineng Health Cell Industry (Hainan) Co., Ltd., purchasing equity from Yuaneng Cell Technology Group Co., Ltd. and Yuaneng Cell (Lishui) Industrial Development Co., Ltd. [1] - The target companies include Shanghai Yuan Tian Biotechnology Co., Ltd., Lishui Dongxin Pharmaceutical Co., Ltd., Shanghai Kelemao Biotechnology Co., Ltd., and Jiyuan Meiyu Biotechnology (Shanghai) Co., Ltd. [1][2]. Group 2: Business Focus of Target Companies - The target companies cover various sectors such as cell preparation, laboratory animal services, and cell technology cosmetics [2]. - Shanghai Yuan Tian focuses on stem cell and immune cell preparation technologies, holding 44 authorized patents [2]. - Lishui Dongxin serves as an investment holding platform without substantial operations, while its subsidiary provides laboratory animal breeding and experimental support [2]. - Jiyuan Meiyu specializes in skin cell repair and regeneration technology, and Kelemao has not yet commenced operations [2]. Group 3: Strategic Implications - The acquisition is intended to enhance Kaineng Health's strategic layout in the health industry and improve its overall competitiveness and sustainable development capabilities [2]. - Entering the stem cell industry aligns with the company's long-term strategic development plan [2].

Core Insights - The article discusses the upcoming conference titled "Stem Cell Biology: From Embryogenesis to Aging and Therapy," organized by Westlake Laboratory and Westlake University, scheduled for November 19-21, 2025, in Hangzhou, China [1][5]. Conference Details - The conference will focus on the role of stem cells in various biological processes, including embryonic development, tissue homeostasis, and potential therapeutic applications for diseases such as neurodegeneration and organ failure [1]. - Registration for the conference is now open globally, with an extension for poster submissions due to high interest [1]. Academic Committee and Speakers - The academic committee includes prominent figures such as Yu Hongtao, Pei Duanqing, and several distinguished researchers from various institutions [2][4]. - The event will feature keynote speakers from renowned universities, including Linda Partridge from University College London and Toshiro Sato from Keio University, among others [7][10]. Program Structure - The conference will consist of multiple sessions covering topics such as embryogenesis, aging, and stem cell therapy, with a detailed agenda planned for each day [33][35]. - There will be opportunities for poster presentations and a "Meet the Editors" session to facilitate networking and academic collaboration [38]. Registration Fees - The registration fees vary based on the timing and category of participants, with specific rates for students, external registrants, and corporate representatives [41].

Core Insights - The biopharmaceutical industry in Hainan has reached a scale of 50 billion yuan, with industrial output exceeding 27 billion yuan, as the Hainan Free Trade Port approaches its operational closure [1][2] - The event held in Haikou focused on modern biopharmaceuticals and high-end food processing, gathering over 300 representatives to explore new development paths for these industries [1] - High-end food processing has achieved an average annual growth rate of 20.5% in industrial added value during the 14th Five-Year Plan period, positioning it as a core sector for Hainan's high-quality development [1] Industry Development - The event facilitated discussions on regional advantages, policy frameworks, cluster effects, and future trends in Hainan's modern biopharmaceutical and high-end food industries [1] - Four rounds of key project signings were completed, covering various subfields such as stem cell research, biopharmaceutical production bases, deep processing of tropical fruits and vegetables, and health food production [1] Strategic Initiatives - The event utilized a comprehensive approach of "policy interpretation + park promotion + enterprise sharing + project signing" to create a high-end platform for government-enterprise dialogue and regional collaboration [2] - This initiative aims to help enterprises seize investment opportunities in the Free Trade Port and promote the formation of a new development pattern characterized by "biopharmaceutical clustering and high-end food processing" [2]

Core Insights - The article emphasizes the growing interest in stem cell research as a revolutionary hope for human health, transitioning from basic research to clinical applications and regenerative medicine [1][3]. Conference Overview - The "Stem Cell Biology: From Embryonic Development to Aging and Therapy" conference will be held from November 19-21, 2025, at Westlake University, Hangzhou, China [14][26]. - The conference aims to explore various aspects of stem cell biology, including embryogenesis, aging, cell reprogramming, tissue repair, and regenerative medicine [12][16]. Key Themes and Topics - The conference will cover core topics such as organ development, cellular clonality and lineage, tissue repair, and stem cell therapy [16][24]. - It will provide a platform for academic exchange and collaboration among global scientists in the field of stem cell research [12][16]. Notable Speakers - Keynote speakers include prominent researchers from renowned institutions, such as Linda Partridge from University College London and Magdalena Zernicka-Goetz from California Institute of Technology [28][31]. - The organizing committee consists of distinguished members from Westlake University and editors from top life science journals [9][14]. Registration and Participation - Registration fees vary based on the timing and participant category, with early registration discounts available [48]. - Participants can submit academic posters for evaluation, with selected posters displayed during the conference [48].